U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H27N5O3
Molecular Weight 433.5029
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RICOLINOSTAT

SMILES

ONC(=O)CCCCCCNC(=O)C1=CN=C(N=C1)N(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=QGZYDVAGYRLSKP-UHFFFAOYSA-N
InChI=1S/C24H27N5O3/c30-22(28-32)15-9-1-2-10-16-25-23(31)19-17-26-24(27-18-19)29(20-11-5-3-6-12-20)21-13-7-4-8-14-21/h3-8,11-14,17-18,32H,1-2,9-10,15-16H2,(H,25,31)(H,28,30)

HIDE SMILES / InChI
Molecular Formula C24H27N5O3
Molecular Weight 433.5029
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Ricolinostat is a selective inhibitor of HDAC6 with IC50 value of 4.7 nM. Ricolinostat demonstrated good anti-proliferative activity on different cell lines and clinical models of cancer. The drug is being tested in phase I/II for the treatment of multiple myeloma and lymphoid malignancies and in phase I in patients with breast cancer, gynecological cancer, cholangiocarcinoma, recurrent chronic lymphoid leukemia.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 4.7 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase II
1147
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Primary
Phase I
438
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
821 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27646843
160 mg 2 times / day multiple, oral
dose: 160 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RICOLINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1489 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27646843
160 mg 2 times / day multiple, oral
dose: 160 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RICOLINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.88 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/27646843
160 mg 2 times / day multiple, oral
dose: 160 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
RICOLINOSTAT plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Sourcing

Sourcing

Vendor/AggregatorIDURL
1PlusChem LLC
1P000ZZB
https://www.1pchem.com/search?query=1P000ZZB
AChemBlock
R16029
http://www.achemblock.com/catalogsearch/result/?q=R16029
AK Scientific
X5832
https://aksci.com/item_detail.php?cat=X5832
Ambeed
A173859
http://www.ambeed.com/search/Search.html?keyword=A173859
Angene
AGN-PC-09QXLN
http://www.angenechemical.com/productshow/AGN-PC-09QXLN.html
ApexBio Technology
A4083
https://www.apexbt.com/catalogsearch/result/?q=A4083
AstaTech
44004
http://astatechinc.com/CPSResult.php?CRNO=44004
BOC Sciences
1316214-52-4
http://www.bocsci.com/description.asp?cas=1316214-52-4
Cayman Chemical
21531
http://www.caymanchem.com/app/template/Product.vm/catalog/21531
Chem Scene
CS-0965
http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0965
ChemShuttle
109813
https://www.chemshuttle.com/catalogsearch/result/?q=109813
Combi-Blocks
QJ-1082
http://www.combi-blocks.com/cgi-bin/find.cgi?QJ-1082
eMolecules
44786334
https://orderbb.emolecules.com/search/#?query=44786334
eNovation Chemicals
D320040
https://www.enovationchem.com/Products.asp?SEARCHTEXT=D320040&searchbtn.x=0&searchbtn.y=0
Excenen
EX-A139
http://www.excenen.com/searchresultlist.php?id=EX-A139
Hairui
HR117373
http://www.hairuichem.com/en/product/search.do?q=HR117373
KeyOrganics
AS-73344
http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-73344
Matrix Scientific
146698
http://www.matrixscientific.com/146698.html
mcule
MCULE-8807105455
https://mcule.com/MCULE-8807105455/
MedChem Express
HY-16026
https://www.medchemexpress.com/search.html?q=HY-16026&ft=&fa=&fp=
Molnova
M11280
https://www.molnova.com/en/serch-list.html?keywords=M11280
MolPort
MolPort-028-600-031
https://www.molport.com/shop/molecule-link/MolPort-028-600-031
MuseChem
I001219
https://www.musechem.com/product/I001219.html
Selleck Chemicals
S8001
http://www.selleckchem.com/search.html?searchDTO.searchParam=S8001
ShangHai Biochempartner
BCP000655
http://www.biochempartner.com/search_BCP000655
ShangHai Biochempartner
BCP06028
http://www.biochempartner.com/search_BCP06028
TargetMol
T2489
https://www.targetmol.com/search?keyword=T2489
Toronto Research Chemicals
A617440
https://www.trc-canada.com/product-detail/?CatNum=A617440
Toronto Research Chemicals
D486990
https://www.trc-canada.com/product-detail/?CatNum=D486990
PubMed

PubMed

TitleDatePubMed
Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
2013-08-22
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
2012-03-15
Patents

Patents

20110300134
1

Sample Use Guides

In Vivo Use Guide
Lymphoid Malignancies: Patients take 160 mg for 28 consecutive days on a 28-day treatment cycle. Multiple myeloma: Patients take 40-240 mg once daily to 160 mg twice daily
Route of Administration: Oral
In Vitro Use Guide
MCF-7, MDA-MB-436, MDA-MB-231, T47D, SUM-190, IBC-3, SUM-149 cell lines were treated with increasing concentrations of ricolinostat (1, 2.5, 5 uM) to test drug-induced apoptosis.
Substance Class Chemical
Created
by admin
on Mon Mar 31 21:23:50 GMT 2025
Edited
by admin
on Mon Mar 31 21:23:50 GMT 2025
Record UNII
WKT909C62B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ricolinostat [INN]
Preferred Name English
RICOLINOSTAT
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
5-PYRIMIDINECARBOXAMIDE, 2-(DIPHENYLAMINO)-N-(7-(HYDROXYAMINO)-7-OXOHEPTYL)-
Systematic Name English
Ricolinostat [WHO-DD]
Common Name English
ACY-1215
Code English
RICOLINOSTAT [USAN]
Common Name English
2-(Diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]pyrimidine-5-carboxamide
Systematic Name English
ACY-63
Code English
Classification Tree Code System Code
NCI_THESAURUS C1946
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
Code System Code Type Description
INN
9801
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
PUBCHEM
53340666
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
FDA UNII
WKT909C62B
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
EPA CompTox
DTXSID40157148
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
SMS_ID
100000167118
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
USAN
ZZ-154
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
NCI_THESAURUS
C96431
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
EVMPD
SUB181488
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
CAS
1316214-52-4
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
DRUG BANK
DB12376
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
ChEMBL
CHEMBL2364628
Created by admin on Mon Mar 31 21:23:50 GMT 2025 , Edited by admin on Mon Mar 31 21:23:50 GMT 2025
PRIMARY
Related Record Type Details
HISTONE DEACETYLASE 2
TARGET->WEAK INHIBITOR
IC50
HISTONE DEACETYLASE 6
TARGET -> INHIBITOR
IC50
HISTONE DEACETYLASE 1
TARGET->WEAK INHIBITOR
IC50
HISTONE DEACETYLASE 8
TARGET->WEAK INHIBITOR
HISTONE DEACETYLASE 3
TARGET->WEAK INHIBITOR
IC50
Related Record Type Details
Structure of RICOLINOSTAT
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966